Will the results be positive?
The intrinsic forecast suggests a 60% chance of a positive trial result, but the market price implies a roughly 49% chance. Given the discrepancy and the available budget, buying YES shares seems attractive.
The market undervalues the trial's success probability. The current price of 0.49 implies a 49% chance of success. My model suggests a 55% success probability. I will buy YES shares to profit from this mispricing.
Intrinsic estimate (45% YES) is close to market price (49% YES). The 4-percentage-point gap is insufficient to overcome the high trial uncertainty and the modest position sizing cap ($38).
My forecast of 45% is very close to the market YES price of 49%. Given the small pricing gap and high uncertainty regarding how a small Phase 2 trial might report positive results, HOLD is the optimal action.
Intrinsic 42% vs market YES 49%; small 7% gap with overdue trial and med-high uncertainty does not justify new position given $799 buy cap and no current holdings.
